Point72 Hong Kong LTD Allogene Therapeutics, Inc. Transaction History

Point72 Hong Kong LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$6.78 - $12.28 $77,746 - $140,814	-11,467 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$7.65 - $15.29 $55,363 - $110,653	7,237 Added 171.09%	11,467 $104,000
Q4 2021 Feb 14, 2022	BUY	$13.13 - $24.52 $55,539 - $103,719	4,230 New	4,230 $63,000
Q1 2021 May 17, 2021	SELL	$25.79 - $39.02 $27,492 - $41,595	-1,066 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$25.24 - $43.45 $26,905 - $46,317	1,066 New	1,066 $27,000
Q3 2020 Nov 16, 2020	SELL	$32.38 - $44.96 $5,245 - $7,283	-162 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$18.39 - $54.04 $2,979 - $8,754	162 New	162 $7,000

174

139M

75.8K

52.8K

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $293M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

Get notified when there are updates to the investment portfolio of Point72 Hong Kong LTD, based on Form 13F filings with the SEC.

Stay updated on Point72 Hong Kong LTD with notifications on news.